Robust safety monitoring and signal detection using alternatives to the standard poisson distribution

被引:0
作者
Duncan, Benjamin [1 ]
机构
[1] AbbVie Inc, Safety Stat Data & Stat Sci, 1 N Waukegan Rd, N Chicago, IL 60064 USA
关键词
Clinical trials; signal detection; under-dispersion; right-censored Poisson model; log-logistic distribution; Bayesian; incidence count; simulation; TRIALS;
D O I
10.1080/10543406.2024.2395532
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Proper and timely characterization of the safety profile of a pharmaceutical product under development is imperative for assessing the overall benefit-risk relationship of the product and for making key development decisions. For ongoing clinical development, a comprehensive and robust safety monitoring and safety signal detection program which is based upon quantitative statistical reasoning is critical. Methods presented here can be applied to safety signal detection and periodic safety monitoring. Various statistical properties, distributions, and models, all utilizing a Bayesian framework are considered and further examined in order to identify robust methods applicable to a broad set of scenarios and situations. Methods developed for incidence counts (including those with under-dispersed distributions) with variable time-at-risk and with underlying constant or non-constant hazard rates, are proposed and compared to traditional methods designed to assess adverse event incidence rates or binomial incidence proportions (which assume an underlying constant hazard rate and subsequent Poisson distribution for modeling event counts).
引用
收藏
页数:18
相关论文
共 23 条
[11]   Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases [J].
Leroy, Fanny ;
Dauxois, Jean-Yves ;
Theophile, Helene ;
Haramburu, Francoise ;
Tubert-Bitter, Pascale .
BMC MEDICAL RESEARCH METHODOLOGY, 2014, 14
[12]   Bridging blinded and unblinded analysis for ongoing safety monitoring and evaluation [J].
Lin, Li-An ;
Zhan, Yilei ;
Li, Hal ;
Yuan, Shuai Sammy ;
Ball, Greg ;
Wang, William .
CONTEMPORARY CLINICAL TRIALS, 2019, 83 :81-87
[13]   Monitoring device safety in interventional cardiology [J].
Matheny, ME ;
Ohno-Machado, L ;
Resnic, FS .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2006, 13 (02) :180-187
[14]   Bayesian detection of potential risk using inference on blinded safety data [J].
Mukhopadhyay, Saurabh ;
Waterhouse, Brian ;
Hartford, Alan .
PHARMACEUTICAL STATISTICS, 2018, 17 (06) :823-834
[15]  
Munsaka M., 2022, Quantitative drug safety and benefit risk evaluation: Practical and cross-disciplinary approaches, P119
[16]   Modeling and Simulation of Count Data [J].
Plan, E. L. .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (08)
[17]   A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded Data [J].
Schnell, Patrick M. ;
Ball, Greg .
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (06) :833-838
[18]  
Suleiman IN, 2017, HACET J MATH STAT, V46, P525
[19]   Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application [J].
Van Wijk, Rob C. ;
Simonsson, Ulrika S. H. .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (08) :991-1001
[20]  
Wang W., 2022, Quantitative drug safety and benefit risk evaluation: practical and cross-disciplinary approaches, P119